ARWR Stock Price Today (May 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-05-22
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $74.95, down 0.78% today (as of May 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $84.50 (12.7% upside).
- Volatility remains elevated (52.30% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (104.61% YoY) alongside significant competitive pressures.
ARWR Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $10.86B
P/E Ratio
Forward P/E: -18.15
Revenue Growth
Year over Year
Analyst Target
+12.7% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 50.97)
- Fundamentals say: Caution warranted (high leverage concerns)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $698.16M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $12.44 and $79.48—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 52.30% annualized volatility and β=1.29, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum
Recent performance snapshot Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after its stock moved in recent sessions, with recent returns over the past week, month and past 3 months prompting closer scrutiny of its current valuation and fundamentals. See our latest analysis for Arrowhead Pharmaceuticals. At around $79.04, Arrowhead Pharmaceuticals’ recent 1-month share price return of 21.34% and very large 1-year total shareholder return of 417.28% point to strong momentum,...
Arrowhead (ARWR) Q2 2026 Earnings Transcript
Arrowhead is now on the strongest footing of our history. As you recall, the FDA approved REDEMPLO in November 2025 as an adjunct to diet to reduce triglycerides in adults with FCS. Greater than 400 prescriptions have been written since launch and more than 10% of these have been for patients switching from our competitors' APOC3 inhibitor.
Arrowhead Pharmaceuticals Q2 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) highlighted continued commercial traction for REDEMPLO and outlined multiple anticipated clinical catalysts in the second half of 2026 as the company reported fiscal 2026 second-quarter results for the period ended March 31, 2026. REDEMPLO launch momentum and
Arrowhead and Madrigal sign global licence for MASH RNAi therapy
Madrigal will pay $25m upfront to Arrowhead, which may receive up to $1bn total to gain access to ARO-PNPLA3.
Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors?
In April 2026, Arrowhead Pharmaceuticals announced an exclusive worldwide license agreement granting Madrigal Pharmaceuticals global rights to develop, manufacture, and commercialize ARO-PNPLA3, an RNA interference therapeutic for metabolic dysfunction-associated steatohepatitis (MASH) supported by Phase 1 data in The New England Journal of Medicine showing meaningful liver fat reduction and a well-tolerated safety profile. This agreement broadens Madrigal’s MASH-focused pipeline beyond its...
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS
Arrowhead Pharmaceuticals’ REDEMPLO (plozasiran), a small interfering RNA therapy, was recently approved by Australia’s Therapeutic Goods Administration as the first and only medicine to reduce triglyceride levels in adults with familial chylomicronemia syndrome when standard treatments are inadequate. This latest approval, backed by the PALISADE Phase 3 data showing very large median triglyceride reductions and fewer acute pancreatitis events, further extends REDEMPLO’s global footprint...
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher […]
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $74.95. The RSI (14-day) is at 51.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $84.50 implies 12.7% upside from current levels. Volatility is high at 52.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is 48.51, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is -18.15, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 18.76. Price-to-Sales is 9.96. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ARWR, the consensus price target is $84.50. This represents a 12.7% upside from the current price of $74.95. The range spans from a low target of $35.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. High volatility (52.3% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 124.07) which could pressure margins in a rising rate environment. 3. Elevated short interest (12.0% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $698.16M. The debt-to-equity ratio is 124.07, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.38, indicating strong short-term liquidity. The quick ratio is 3.26. The company holds $914.71M in cash and equivalents. Free cash flow is positive at $170.73M, providing a cushion for debt servicing and shareholder returns.